Adial Pharmaceuticals (ADIL) Competitors $0.96 -0.08 (-7.69%) Closing price 01/17/2025 03:59 PM EasternExtended Trading$1.01 +0.05 (+5.21%) As of 09:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ADIL vs. DRRX, CDIO, ATHE, LVTX, GDTC, EQ, ENLV, LPCN, MRKR, and BCABShould you be buying Adial Pharmaceuticals stock or one of its competitors? The main competitors of Adial Pharmaceuticals include DURECT (DRRX), Cardio Diagnostics (CDIO), Alterity Therapeutics (ATHE), LAVA Therapeutics (LVTX), CytoMed Therapeutics (GDTC), Equillium (EQ), Enlivex Therapeutics (ENLV), Lipocine (LPCN), Marker Therapeutics (MRKR), and BioAtla (BCAB). These companies are all part of the "pharmaceutical products" industry. Adial Pharmaceuticals vs. DURECT Cardio Diagnostics Alterity Therapeutics LAVA Therapeutics CytoMed Therapeutics Equillium Enlivex Therapeutics Lipocine Marker Therapeutics BioAtla Adial Pharmaceuticals (NASDAQ:ADIL) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation, earnings and community ranking. Do analysts prefer ADIL or DRRX? Adial Pharmaceuticals currently has a consensus price target of $8.00, suggesting a potential upside of 733.33%. DURECT has a consensus price target of $5.00, suggesting a potential upside of 488.30%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Adial Pharmaceuticals is more favorable than DURECT.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adial Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50DURECT 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility and risk, ADIL or DRRX? Adial Pharmaceuticals has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, DURECT has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Do insiders & institutionals believe in ADIL or DRRX? 16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 28.0% of DURECT shares are held by institutional investors. 5.2% of Adial Pharmaceuticals shares are held by insiders. Comparatively, 3.2% of DURECT shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better earnings & valuation, ADIL or DRRX? Adial Pharmaceuticals has higher earnings, but lower revenue than DURECT. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdial PharmaceuticalsN/AN/A-$5.12MN/AN/ADURECT$8.55M3.09-$27.62M-$0.61-1.39 Does the MarketBeat Community believe in ADIL or DRRX? DURECT received 206 more outperform votes than Adial Pharmaceuticals when rated by MarketBeat users. Likewise, 62.95% of users gave DURECT an outperform vote while only 58.51% of users gave Adial Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAdial PharmaceuticalsOutperform Votes11058.51% Underperform Votes7841.49% DURECTOutperform Votes31662.95% Underperform Votes18637.05% Is ADIL or DRRX more profitable? Adial Pharmaceuticals has a net margin of 0.00% compared to DURECT's net margin of -198.58%. Adial Pharmaceuticals' return on equity of -168.25% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets Adial PharmaceuticalsN/A -168.25% -148.46% DURECT -198.58%-300.62%-65.17% Does the media refer more to ADIL or DRRX? In the previous week, Adial Pharmaceuticals' average media sentiment score of 1.00 beat DURECT's score of 0.89 indicating that Adial Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Adial Pharmaceuticals Positive DURECT Positive SummaryAdial Pharmaceuticals beats DURECT on 9 of the 14 factors compared between the two stocks. Get Adial Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADIL vs. The Competition Export to ExcelMetricAdial PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.15M$6.52B$5.34B$9.11BDividend YieldN/A2.96%5.37%4.00%P/E RatioN/A4.4457.4913.22Price / SalesN/A310.281,275.6876.05Price / CashN/A22.6336.6032.90Price / Book0.394.964.874.58Net Income-$5.12M$154.90M$118.05M$224.84M7 Day Performance-5.88%1.38%1.50%2.37%1 Month Performance-10.28%0.44%2.55%4.40%1 Year Performance-24.71%3.11%25.83%20.11% Adial Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADILAdial Pharmaceuticals3.6736 of 5 stars$0.96-7.7%$8.00+733.3%-24.7%$6.15MN/A0.0020Positive NewsGap DownDRRXDURECT4.0353 of 5 stars$0.83+7.0%$5.00+506.1%+16.1%$25.61M$8.59M-1.3580CDIOCardio Diagnostics2.5122 of 5 stars$0.63-6.4%$2.00+218.5%-76.1%$25.40M$35,688.000.007ATHEAlterity Therapeutics2.1546 of 5 stars$3.45+3.3%$6.00+73.9%+83.9%$25.20MN/A0.0010Short Interest ↑LVTXLAVA Therapeutics3.1165 of 5 stars$0.99+1.5%$3.33+236.7%-40.9%$25.10M$7.35M-0.9660Positive NewsGDTCCytoMed Therapeutics1.444 of 5 stars$2.26-18.1%$5.00+121.2%-39.0%$24.72MN/A0.00N/AEQEquillium2.2473 of 5 stars$0.70-0.8%$5.00+619.3%-22.3%$24.63M$45.91M-4.9640ENLVEnlivex Therapeutics3.6144 of 5 stars$1.15+0.4%$9.50+726.1%-58.8%$24.62MN/A-1.1770Positive NewsLPCNLipocine2.6034 of 5 stars$4.59-6.1%$10.00+117.9%+15.9%$24.55M$7.92M-6.0410News CoveragePositive NewsMRKRMarker Therapeutics4.0994 of 5 stars$2.74-3.2%$19.00+593.4%-43.1%$24.45M$3.31M0.0060BCABBioAtla2.5605 of 5 stars$0.50-6.1%$6.00+1,102.4%-75.1%$24.13M$11M-0.2960Short Interest ↑Negative NewsGap Up Related Companies and Tools Related Companies DURECT Alternatives Cardio Diagnostics Alternatives Alterity Therapeutics Alternatives LAVA Therapeutics Alternatives CytoMed Therapeutics Alternatives Equillium Alternatives Enlivex Therapeutics Alternatives Lipocine Alternatives Marker Therapeutics Alternatives BioAtla Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ADIL) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
